MacroGenics In Research, License Agreement With Janssen
By Michael Dabaie
MacroGenics Inc. said Friday it is in a research collaboration
and global license agreement with Janssen Biotech Inc.
MacroGenics, a cancer-focused biopharmaceutical company, said
the deal is to develop a preclinical molecule with Janssen. The
research collaboration will incorporate MacroGenics' DART platform
to enable simultaneous targeting of two undisclosed targets in a
therapeutic area outside oncology.
Janssen will pay MacroGenics $20 million upfront and will be
responsible for funding all expenses. MacroGenics can also receive
up to $312 million in potential milestone payments and tiered
royalties on worldwide product sales.
Write to Michael Dabaie at firstname.lastname@example.org
(END) Dow Jones Newswires
December 18, 2020 08:04 ET (13:04 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.